Literature DB >> 2582149

Competitive inhibition by human sera of mouse monoclonal antibody binding to glycoproteins C and D of herpes simplex virus types 1 and 2.

C Ross, J Glorioso, S Sacks, C Lavery, W E Rawls.   

Abstract

A competitive enzyme-linked immunosorbent assay was used to test for human antibodies to antigenic sites on herpes simplex virus (HSV) glycoproteins C and D, which are recognized by mouse monoclonal antibodies. Antibodies capable of blocking the monoclonal antibodies were detected in the human sera, and the inhibition of binding correlated with the histories of herpetic infections. The binding of monoclonal antibody to glycoprotein C of HSV type 2 was inhibited primarily by sera from patients with recurrent herpes genitalis; however, the binding of the monoclonal antibodies to gC of HSV type 1 was inhibited by sera from patients previously infected with either HSV type 1 or HSV type 2. The observations suggest that the antigenic sites defined by the mouse monoclonal antibodies are recognized by the human host.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582149      PMCID: PMC254873     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

2.  The role of type specific and cross reacting structural antigens in the neutralization of herpes simplex virus types 1 and 2.

Authors:  C Sim; D H Watson
Journal:  J Gen Virol       Date:  1973-05       Impact factor: 3.891

3.  Measurement of antibodies to herpesvirus types 1 and 2 in human sera.

Authors:  W E Rawls; K Iwamoto; E Adam; J L Melnick
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

4.  Monoclonal antibodies to two glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; D Harnish; R A Killington; S Bacchetti; W E Rawls
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

5.  Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody.

Authors:  G H Cohen; B Dietzschold; M Ponce de Leon; D Long; E Golub; A Varrichio; L Pereira; R J Eisenberg
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

6.  Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies.

Authors:  L Pereira; D V Dondero; D Gallo; V Devlin; J D Woodie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

7.  Sexual and socioeconomic factors affecting the risk of past infections with herpes simplex virus type 2.

Authors:  K M Stavraky; W E Rawls; J Chiavetta; A P Donner; J M Wanklin
Journal:  Am J Epidemiol       Date:  1983-07       Impact factor: 4.897

8.  Neonatal cytomegalovirus infections: the relative role of neonatal blood transfusion and maternal exposure.

Authors:  W E Rawls; C L Wong; M Blajchman; J Venturelli; J Watts; M Chernesky; S Saigal
Journal:  Clin Invest Med       Date:  1984       Impact factor: 0.825

9.  Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C.

Authors:  R J Frink; R Eisenberg; G Cohen; E K Wagner
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

10.  Localization of a type-specific antigenic site on herpes simplex virus type 2 glycoprotein D.

Authors:  W E Rawls; N Balachandran; G Sisson; R J Watson
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more
  1 in total

1.  Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates.

Authors:  H M Friedman; J C Glorioso; G H Cohen; J C Hastings; S L Harris; R J Eisenberg
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.